TABLE 1.

Overview of the studies stating time‐to‐event analysis in HPV‐related cancer.

No.	Authors and Year	Country	Tumor type	HPV ctDNA quantification	Cases No. in time‐to‐event analysis	Surrogate endpoint assessment (pre‐post‐treatment marker)	Medical treatment for outcome measurement
1	Leung et al. (2021) 31	Canada	LACC	HPV‐seq	16	PFS: EOT detectable HPV ctDNA	CRT
2	Jeannot et al. (2021) 18	France	CC	ddPCR	40	PFS: EOT detectable HPV ctDNA	CRT, Neo‐chemotherapy
						PFS: Baseline detectable HPV ctDNA
3	Cabel et al. (2021) 32	France	LACC	ddPCR	14	DFS: EOT detectable HPV ctDNA	CRT
4	Lefèvre et al. (2021) 33	Denmark	SCCA	ddPCR	45	DFS: Baseline high and low pHPV	CRT
5	Tanaka et al. (2020) 34	Japan	HNSCC	ddPCR	35	EFS: EOT detectable HPV ctDNA 16	Radiotherapy with or without chemotherapy
6	Chera et al. (2020) 35	USA	OPSCC	ddPCR	115	RFS: EOT detectable HPV ctDNA	CRT
7	Chera et al. (2019) 36	USA	OPSCC	ddPCR	48	RDFS a : Baseline favorable and unfavorable clearance HPV ctDNA16	CRT
8	Bernard‐Tessier et al. (2018) 37	France	SCCA	ddPCR	36	PFS: EOT detectable HPV ctDNA	Chemotherapy
9	Cabel et al. (2018) 38	France	ASCC [locally advanced]	ddPCR	18	DFS: EOT detectable HPV ctDNA	CRT
10	Dahlstrom et al. (2015) 26	USA	OPSCC [OPC]	qPCR	99	PFS: Baseline detectable circulating HPV DNA	Chemotherapy and Radiotherapy b
11	Han et al. (2018) 39	Canada	LACC	ddPCR	19	PFS: EOT detectable HPV ctDNA	CRT
12	Routman et al. (2022) 40	USA	OPSCC	ddPCR	159	RFS: EOT detectable HPV ctDNA	Adjuvant radiation therapy
13	Sivars et al. (2022) 41	Sweden	LACC	ddPCR	18	PFS: EOT detectable HPV ctDNA	CRT and EBRT

Abbreviations: CC: cervical cancer; CRT: chemoradiotherapy; DFS: disease‐free survival; EBRT: external beam radiation therapy; EFS, event‐free survival; HNSCC: squamous cell carcinoma of the head and neck; LACC: locally advanced cervical cancer; OPSCC: oropharyngeal squamous cell carcinoma; PFS: progression‐free survival; RDFS: regional disease‐free survival; RFS: recurrence‐free survival; SCCA: Squamous cell carcinoma of the anus; SCCA: squamous cell carcinomas of the anal canal [Anal squamous cell carcinoma (SCCA)].

^a RDFS: was measured from the first CRT dose and defined as the time to detect or develop persistent or recurrent disease in the cervical lymph nodes.

^b During and after treatment, patients underwent regular clinical and radiologic examinations with a team of specialists in head and neck cancer, including surgeons, radiation oncologists, and medical oncologists.